Search
Flotufolastat F-18
go.drugbank.com/drugs/DB17851ApprovedInvestigationalFlotufolastat F-18 (18F-rhPSMA-7.3) is an 18F-labeled ligand that targets the prostate-specific membrane antigen (PSMA). In patients with recurrent prostate cancer that require localized treatment, the use of 18F-labeled ligands for posi...
5'-Guanosine-Diphosphate-Monothiophosphate
go.drugbank.com/drugs/DB01864ExperimentalA stable GTP analog which enjoys a variety of physiological actions such as stimulation of guanine nucleotide-binding proteins, phosphoinositide hydrolysis, cyclic AMP accumulation, and activation of specific
Nelistotug
go.drugbank.com/drugs/DB19334InvestigationalNelistotug is under investigation in clinical trial NCT06062420 (A Platform Study of Novel Immunotherapy Combinations as First-line Treatment in Participants With PD-L1 Positive Recurrent/metastatic Squamous
ZD4407
go.drugbank.com/drugs/DB06539ExperimentalThe drug ZD4407, an antiasthmatic developed by AstraZeneca, functions as a 5-lipoxygenase inhibitor.
TMC-310911
go.drugbank.com/drugs/DB15623InvestigationalTMC-310911 (also known as ASC-09) is a novel investigational protease inhibitor (PI) that is structurally similar to the currently available [darunavir]. … [L12045,A191643] TMC-310911 is currently being investigated, in combination with other HIV therapies and antivirals, as a potential treatment for COVID-19 caused by SARS-CoV-2.[L12012]
ETC-588
go.drugbank.com/drugs/DB05456ExperimentalEsperion is currently developing ETC-588 as a treatment for patients with acute coronary syndromes. … LUV are capable of transporting excess cholesterol from the vasculature to the liver for eventual elimination as part of the reverse lipid transport (RLT) pathway.
Nadide
go.drugbank.com/drugs/DB14128InvestigationalIt is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). (Dorland, 27th ed)
DP-b99
go.drugbank.com/drugs/DB05820InvestigationalDP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment
19-Nor-5-androstenedione
go.drugbank.com/drugs/DB01443ExperimentalIllicitIt is regulated in the United States as a schedule III controlled substance, and prohibited by the World Anti-Doping Agency for use in competitive sports.
ATL1101
go.drugbank.com/drugs/DB05023ExperimentalATL1101 is being developed as a cream for the topical treatment of mild to moderate cases of psoriasis.